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Background. )e purpose of this study was to evaluate the overall survival (OS) and associated characteristics for patients with
Myxoid Liposarcoma (MLS) over time in )e Netherlands. Methods. A population-based study was performed of patients with
primary localized (n� 851) andmetastatic (n� 50)MLS diagnosed in)eNetherlands between 1989 and 2016, based on data from
the National Cancer Registry. Results. )emedian age of theMLS patients was 49 years, and approximately two-thirds was located
in the lower limb. An association was revealed between age and the risk of having a Round Cell (RC) tumor. OS rates for primary
localized MLS were 93%, 83%, 78%, and 66% after 1, 3, 5, and 10 years, respectively. )e median OS for patients with metastatic
disease at diagnosis was 10 months. Increasing age (Hazard Ratio (HR) 1.05, p � 0.00), a tumor size >5 cm (HR 2.18; p � 0.00),
and tumor location (trunk HR 1.29; p � 0.09, upper limbHR 0.83; p � 0.55, and “other” locations HR 2.73; p � 0.00, as compared
to lower limb) were independent prognostic factors for OS. )e percentage of patients treated with radiotherapy (RT) increased
over time, and preoperative RT gradually replaced postoperative RT. In contrast to patients with localized disease, significant
improvement of OS was observed in patients with metastatic disease over time. Conclusions. In this large nationwide cohort,
tumor size and tumor location were independent prognostic factors for OS. Furthermore, a higher probability of an RC tumor
with increasing age was suggested. An increased use of RT over the years did not translate into improved OS for localized MLS.
1. Introduction
Soft Tissue Sarcomas (STSs) are a heterogeneous group of
malignant tumors of mesenchymal origin; therefore, em-
phasis should be given to characteristics of the various
subtypes of STSs in order to adapt treatment strategies to
their biological and clinical behavior. Liposarcomas, char-
acterized by adipocytic differentiation, represent one of the
most commonly encountered types of STSs. Four histologic
subtypes of liposarcoma are recognized: well-differentiated
liposarcoma, dedifferentiated liposarcoma, pleomorphic
liposarcoma, and myxoid liposarcoma (MLS) [1]. Even
among these subtypes, substantial differences exist regarding
histology, cytogenetics, clinical behavior, treatment re-
sponse, and prognosis. MLS, the focus of this study, rep-
resents approximately one-third [2] of all liposarcomas and
10% of all adult STSs [3]. MLS generally presents as a slow-
growing deep-seated tumor with a predilection for the lower
extremity, particularly the groin region [4]. )e peak inci-
dence is the fourth and fifth decades of life, which is notably
younger than for other liposarcoma subtypes [4]. Distant
metastases occur in 14–33% of the patients withMLS [5–13].
In contrast to other STSs, they are characterized by a ten-
dency to metastasize to other soft tissue sites such as the
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extremities, trunk, retroperitoneum, pleura, pericardium,
and even to the bone [2, 14–16]. MLS is relatively sensitive to
radiotherapy (RT) [12, 17, 18] and chemotherapy [19, 20], in
comparison to other STSs. Local control is achieved in
60–98% of patients [4, 7, 8, 11–14, 18, 21–23], resulting in
favorable 5-year overall survival (OS) rates of 67–90%
[5, 9, 11–13, 21, 23–25].Although sample sizes in most of the
previous studies are small due to the rarity of the disease,
several prognostic factors in MLS have been identified. Age
at diagnosis >45years, tumor size >10 cm, presence of >5%
round cell component, and positive resection margins are
associated with worse (disease-specific) survival
[5, 7, 8, 11, 13, 21, 23–25]. To overcome these small sample
sizes and generate sufficient statistical power, national
cancer registries have great potential to come to more de-
finitive conclusions based on unselected observations
[24].)e purpose of this study was to characterize demo-
graphics, with the round cell component in particular (I), OS
rates (II) and prognostic factors (III) for MLS in a na-
tionwide retrospective cohort of 901 patients treated be-
tween 1989 and 2016 in)e Netherlands. Furthermore, time
trends of treatment and OS of MLS were studied (IV).
2. Patients and Methods
2.1. Data Collection. )e data were derived from )e Neth-
erlands Cancer Registry (NCR). )e NCR used the Dutch
Pathology Network (PALGA), supplemented with a linkage
with the National Registry of Hospital Discharge Diagnosis to
identify patients with histologically diagnosed MLS in )e
Netherlands between 1989 and 2016. Demographics, tumor
characteristics, and treatment information were obtained from
hospital records by trained NCR registry administrators. )e
date of death was extracted from the Municipal Personal
Records Database. Tumor size was extracted from the T-stage
in the pathological report, and if not applicable or in case of
neoadjuvant treatment, the clinical T-stage was used. Reported
primary tumor locations were classified to the upper limb,
lower limb, trunk, or “other locations”. Other locations in-
cluded the head and neck, peritoneum, retroperitoneum,
mediastinum, and both male and female genital organs. Dis-
ease was considered to be primary localized in case of lacking
information regarding themetastatic spread, given the very low
proportion of cases with primary metastatic disease versus
primary localized disease [24] and assuming that a detected
distant metastasis at diagnosis is very unlikely not to be re-
ported. A high-grade tumor, from here, termed Round Cell
(RC) tumor, was defined as a tumor containing> 5% of Round
Cell Component (RCC) [6, 7]. RCC was assessed as a prog-
nostic factor for OS, dichotomized to ≤5% or >5% RCC. From
all 903 identified histologically confirmed MLS patients in the
NCR database, two patients were excluded because of emi-
gration-related lost to follow-up, and a total of 901 patients
were included within this study.
2.2. Statistical Analysis. Baseline characteristics are pre-
sented as percentage, mean (±standard deviation), or me-
dian (+interquartile range (IQR)) in case of a skewed
distribution. Differences in baseline characteristics and in
patients with localized versus metastatic disease and MLSs
versus RC tumors were tested using Student’s t-tests
(continuous variables) and Chi-square tests (categorical
variables). )e follow-up duration for all patients was cal-
culated as the time between the date of diagnosis and date of
death or date of most recent linkage with )e Netherlands
Population Registry at January 31st 2017. Follow-up for
patients alive was estimated using the reverse Kaplan–Meier
approach. Patients with primary metastatic disease were
analysed separately. OS was analysed by the Kaplan–Meier
method, and subgroups were compared by Log-Rank tests.
To investigate prognostic factors for OS, aiming to support
doctors in informing their patients about their prognosis in
the consultation room, cox proportional hazard analyses
were performed. A multivariable model was constructed
using a backward selection procedure, including variables
with p values <0.10 [26]. Treatment-related factors were
excluded from the model to prevent indication-to-treat bias.
A Hazard Ratio (HR) is always presented with a 95%
Confidence Interval (CI).Sensitivity analyses were per-
formed to investigate the independent association of RC
tumors. For this, we first constructed a univariate model.
)en, one potential explanatory variable was added, and the
percentual change (∆%) of the HR of the RC tumor variable
was calculated by performing an association cox regression
model. )e localized disease cohort was split into four
groups based on their year of diagnosis (quartiles), in order
to analyse time trends by mutually comparing those quar-
tiles. Given the relatively small number of primary meta-
static cases and, moreover, characterized by a heterogeneity
of sites and number of metastases, the metastatic cohort was
split into two subgroups (before and after the median year of
diagnosis) for time trend analysis, and no prognostic factor
analysis was performed. All tests were two-sided, and
p≤ 0.05 was considered as statistically significant. Statistical
analysis of the data was performed by using IBM SPSS
Statistics V25.
3. Results
3.1.Demographics. In the study population, which consisted
of 512 (57%) males and 389 (43%) females, the median age at
diagnosis was 49 years (IQR 38–62 years). Evidence of
distant metastasis at diagnosis was present in 50 (6%) pa-
tients. An overview of baseline characteristics is presented in
Table 1. In this study population, 77 (9%) of tumors were RC
tumors. Patients with RC tumors were significantly older as
compared to patients with MLS (median age 53 vs. 48 years,
respectively; p � 0.01) (Supplementary Materials Table 1).
)e distribution of the probability of having a RC tumor by
the age group is shown in Figure 1.
3.2. Overall Survival (OS). )e median follow-up for all
patients was 7.6 years (IQR 2.4–15.3 years), 8.3 years (IQR
2.8–15.8 years) for patients with localized and 0.8 years (IQR
0.5–1.9 years) for patients with metastatic disease at diag-
nosis. Median follow-up for patients alive at time of the last
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follow-up was 13.9 years for localized and 5.9 years for
metastatic disease. For all patients with localized disease, the
1-, 3-, 5-, and 10- year OS rates were 93%, 83%, 78%, and
66%, respectively. )e OS rates for localized disease, strat-
ified for age, tumor size, RCC, and tumor location are
provided in Supplementary Materials Table 2. For patients
with metastatic disease at diagnosis, OS rates were signifi-
cantly lower as compared to localized disease (HR 8.71; 95%
CI 6.18–12.28; p � 0.00). OS rates for metastatic disease after
1, 2, and 3 years were 47%, 29%, and 24%, respectively.
3.3. Prognostic Factors in Localized Disease. Increasing age
(HR 1.05; 95% CI 1.05–1.06; p � 0.00), a tumor size> 5 cm
(HR 2.42; 95% CI 1.73–3.37; p � 0.00), RC tumor (HR 1.66;
95% CI 1.20–2.31; p � 0.00), male gender (HR 1.25; 95%
1.00–1.56; p � 0.04), and tumor location (trunk HR 1.74;
95% CI 1.34–2.26; p � 0.00, upper limb HR 0.79; 95% CI
0.47–1.34; p � 0.38, and other HR 3.78; 95% CI 2.82–5.06;
p � 0.00) with the lower limb as the reference location were
found to be significant prognostic factors for OS in uni-
variate analysis. Of note, the lower limb was chosen as the
reference location, as this represented the largest subgroup.
A positive resection margin (HR 0.92; 95% CI 0.57–1.51;
p � 0.75) did not turn out to be prognostic for OS in
univariate analysis. In multivariate analysis, increasing age
(HR 1.05; 95% CI 1.04–1.06; p � 0.00), a tumor size> 5 cm
(HR 2.24; 95% CI 1.59–3.16; p � 0.00), and tumor location
(trunk HR 1.29; 95% CI 0.96–1.72, upper limb HR 0.83; 95%
CI 0.46–1.52, and other HR 2.73; 95% CI 1.93–3.87, overall p
value p � 0.00) remained significant prognostic factors for
OS, while RC tumor (HR 1.39; 95% CI 0.97–1.98; p � 0.07)
and male gender (HR 1.24; 95% CI 0.97–1,58, p � 0.09) did
not reach statistical significance. Age and tumor size both
Table 1: Baseline characteristics of patients with localized and metastatic disease at diagnosis.
Characteristics Localized disease Metastatic disease Total p value
Total patients (n� ) 851 50 901
Median follow-up (years)(IQR) 8.3 [2.8–15.8] 0.8 [0.5–1.9] 7.6 [2.4–15.3] 0.000
Gender N.S
Male 480 (56%) 32 (64%) 512 (57%)
Female 371 (44%) 18 (36%) 389 (43%)
Tumor location N.S.
Upper limb 51 (6%) 2 (4%) 53 (6%)
Lower limb 551 (65%) 26 (52%) 577 (64%)
Trunk 170 (20%) 15 (30%) 185 (21%)
Other 79 (9%) 7 (14%) 86 (9%)
Tumor grade N.S.
Intermediate grade (MLS) 779 (92%) 45 (90%) 824 (91%)
High grade (RC tumor) 72 (8%) 5 (10%) 77 (9%)
Age (years) 0.004
<40 238 (28%) 8 (16%) 352 (39%)
40–55 304 (36%) 16 (32%) 312 (35%)
56–70 204 (25%) 16 (32%) 169 (19%)
>70 105 (12%) 10 (20%) 68 (7%)
TNM classification 0.000
pT0 12 (1%) 1 (2%) 13 (1%)
pT1 173 (20%) 0 173 (19%)
pT2 502 (59%) 18 (36%) 520 (58%)
pTx 164 (19%) 31 (62%) 195 (22%)
cN0 569 (67%) 21 (42%) 590 (66%)
cN1 2 (0%) 5 (10%) 7 (1%)
cNx 280 (33%) 24 (48%) 304 (34%)
cM0 648 (76%) 0 648 (72%)
cM1 0 50 (100%) 50 (6%)
cMx 203 (24%) 0 203 (23%)
Surgical resection 0.000
Radical (R0) 368 (43%) 4 (8%) 372 (41%)
Microscopic irradical(R1) 57 (7%) 2 (4%) 59 (7%)
Macroscopic irradical (R2) 15 (2%) 7 (14%) 22 (2%)
Unknown status (Rx) 366 (43%) 8 (15%) 374 (42%)
No surgery 45 (5%) 29 (58%) 74 (8%)
Other treatments 0.000
Radiotherapy (RT) 452 (53%) 14 (28%) 466 (52%)
Chemotherapy 50 (6%) 19 (38%) 69 (8%)
)e P value represents outcome of Chi-square statistical testing (or the Student’s t-test in case of an continuous variable). Abbreviations: pT�pathological T-
stage, cN� clinical nodal stage, cM� clinical metastasis stage, N.S.� not significant.
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explained the association between RC tumors and OS in
univariate analysis. After correction for both, the association
was attenuated and lost statistical significance (HR 1.36; 95%
CI 0.95–1.93; p � 0.09) (Supplementary Materials Table 3).
3.4. Time Trends. For localized disease, no significant dif-
ferences in OS were observed between the four follow-up
periods, as shown in Figure 2 . OS rates at 1, 3, and 5 years
were 93%, 80%, and 75% in the first period (1989–1995)
versus 92%, 87%, and 81% in the last period (2009–2016),
respectively (p � 0.17). In contrast to patients with localized
disease, significant improvement in OS rates for patients
with primary metastatic disease was observed within the
time frame of the study. Median OS for primary metastatic
disease increased from 9 months in 1989–2002 to 20 months
in 2003–2016. Kaplan–Meier curves of patients divided into
the two groups by the year of diagnosis are presented in
Figure 3. With respect to time trends in RT treatments, an
increase in the use of RT was observed during the study
period (Figure 4). Where only 38% of the patients in the first
period (1989–1995) received RT, and this was 76% in the
most recently diagnosed group of patients (2009–2016,
p � 0.00). Furthermore, postoperative RT was gradually
replaced by preoperative RT from 2004 onwards, with a
preoperative timing of the RT in 23%, 59%, and 83% of the
irradiated patients in 2005, 2010, and 2015, respectively.
4. Discussion
In this large nationwide cohort of MLS patients, tumor size
and location were found to be independent prognostic
factors for OS in localized MLSs. Secondly, an association
between a higher incidence of RC tumors and increasing age
was revealed. Furthermore, we observed an increased ap-
plication of, particularly preoperative, RT over time. Prog-
nosis of patients with primary metastatic disease has
significantly improved over the years; however, we were
unable to demonstrate a significant increase of OS rates for
patients with localized disease in recent years. )is study
confirms the well-established peak incidence [4] and the
predilection for males and lower extremities in MLS
[5, 8, 10, 12, 24, 27]. In previous series, 7–43% of all MLS
were classified as round-cell tumors [5, 7–12], with most
authors using RCC cut-off points of 5% [7–12], though some
others at 25% [5, 7]. In this series, nearly one in ten tumors
was a RC tumor (>5% RCC), belonging to the lowest in-
cidences in the literature. )e relationship between age and
the incidence of RC tumors has not been reported previ-
ously, but was suggested in this study cohort, with a higher
probability of having a RC tumor for older patients and an
increase of approximately 2% per additional year of age. RC
tumors are reported to be associated with inferior outcomes
as compared to MLS, with an assumed three to four times
higher risk of local recurrence [9, 21] and a higher tendency
to metastasize [7, 10], leading to decreased (disease-specific)
survival rates in several studies [6, 7, 10]. )is reported
inferior OS for RC tumors was confirmed in the current
study. Furthermore, we showed that both tumor size and
increasing age explained part, but not the entire association
between RC tumors and OS. )ese findings might reveal an
important subgroup ofMLS patients with worse OS in an era
of personalized care. More research is needed to determine
optimal treatment strategies for these elderly patients with
larger tumors with >5% RCC. Obviously, age is a significant
prognostic factor in our predictive model, as the outcome
measure was OS and not cause-specific survival. We have
incorporated age in the model to rule out its role as a
confounding factor for other prognostic factors. In accor-
dance with previous reports [8, 10, 23, 28], tumor size was
confirmed as independent prognostic factor for OS. Un-
fortunately, the exact tumor size was not available in our
database, necessitating us to use the T-stage to derive tumor
size information. For that reason, we used 5 cm as a cut-off
point for tumor size, instead of the 10 cm cut-off used in
most other studies [8, 10, 11, 24, 25]. Even though tumor
location is generally considered as a prognostic factor in
STSs [27], and to the best of our knowledge, it has never been
reported as a prognostic factor for OS in MLS to date. Here,
an association between tumor location and OS in MLS was
observed; in comparison to the lower extremity, tumors at
“other” locations, with the majority consisting of retro-
peritoneal tumors, have significantly worse OS, independent
of confounding factors (HR 2.73, p � 0.00). Potential con-
tributing factors for worse outcome in retroperitoneal tu-
mors include the challenges of local treatment caused by the
complex anatomy of the surgical area. Furthermore,
according to the results of immunohistochemical and mo-
lecular biological analyses by de Vreeze et al. [29], primary
retroperitoneal MLS/RC tumor might be a nonexisting
disease, suggesting that a retroperitoneal location either is a
metastasis or a misclassified well-/dedifferentiated lip-
osarcoma with the presence of focal myxoid-like changes. In
conformity with this hypothesis, the supposed localized
“other” location group might contain patients with metas-
tasized disease, resulting in worse OS rates. Tumor location
in the trunk did not reach statistical significance in multi-
variate analysis (HR 1.29, p � 0.09), but had significantly





































Figure 1: )e frequency/proportion of tumors with a RC tumor
per age group in localized disease. Overall p value by the Chi-
square test p � 0.08.
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Figure 2: Kaplan–Meier curves representing OS of patients with primary localized disease divided in four groups by the period of diagnoses,



























Figure 3: Kaplan–Meier curves representing OS of patients with primary metastasized disease in the period of 1989–2002 vs. 2003–2016, as
compared by the log-rank test (p � 0.011).
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older, as compared to patients with a tumor located in the
lower extremity. With a 5-year OS rate of 78.1% for localized
disease, OS is comparable to the rates of 67–94% reported in
the literature [5, 9, 11–13, 21, 24]. Prognosis of metastatic
disease did improve significantly during the study period,
within the last decade in particular. Since 2003 (median year
of diagnosis), approximately 40% of patients with metastatic
disease at diagnosis were alive 3 years after diagnosis, as
compared to 8% of this cohort’s patients diagnosed before
2003 and 22% in the study reported by Hoffman et al.
(inclusion in the period of 1990–2010) [30]. Advances in
imaging techniques, increasing the sensitivity to detect
metastases, leading to stage migration, and the introduction
of novel systemic therapies (such as trabectedin and eri-
bulin), as well as more aggressive local treatment for me-
tastases including RTmay have impacted this improvement
[31, 32]. Nevertheless, although consistent with previous
reports [24, 28, 33], these diagnostic and therapeutic ad-
vances did not translate into significantly improved OS for
patients with primary localized disease in recent years. As
most of the previously described advances merely affect
patients with metastatic disease, while approximately two
out of three patients will eventually not metastasize
[5, 7, 8, 10, 11, 13, 18], relative gains of these advances are
smaller in comparison to the primary metastatic disease
cohort. On the other hand, the potential of OS improvement
by introduction of effective systemic treatments could
possibly have been hampered by the small proportion of
patients with localized MLS receiving chemotherapy (6%) as
part of their primary treatment. When looking to the
Kaplan–Meier curves for localized disease in detail, one can
argue that a trend for improved OS is seen in recent years,
which could possibly reach statistical significance with
longer follow-up. )e use of RT increased and its timing to
surgery has changed, which is in line with the time trends
reported by Lazarev et al. [34]. Where RTwas applied strictly
in the postoperative setting during the first years of the study
period, the use of preoperative RT in )e Netherlands
commenced in 2004 and from 2010 it even is used more
frequently than postoperative RT. )e most important
limitation of this population-based analysis is the restriction
to the variables and outcomes registered by the NCR. For
this reason, it was unable to provide local tumor control,
metastasis-free-survival, and disease-specific survival as an
endpoint in our study. Furthermore, there are some un-
certainties regarding the pathology diagnoses. Although data
with respect to the translocation status is lacking, MLS
diagnoses generally have been translocation confirmed in
the last decade of the study period; however, this would not
have been the case in earlier years, when molecular diag-
nostics were not widely available for clinical practice yet.
)is implicates that the spectrum of myxoid and RC tumors
could have changed over the years. Moreover, no central
pathology review was performed, although it is custom in
)e Netherlands to send cases to monthly regional sarcoma
pathology board meetings. Lastly, it is important to be aware
that recurrences are possible after our median follow-up
period of 7.6 years, as the latest reported recurrence occurred
at 151 months [9].
5. Conclusions
)is large nationwide study showed that OS is indepen-
dently affected by the tumor size and tumor location in
MLSs. Furthermore, a higher probability of a RC tumor with
increasing age was suggested.We observed an increase in the
use of RTin)eNetherlands, with a shift from postoperative
to preoperative timing in the most recent decade. Never-
theless, OS rates of primary localized MLS remained stable
over time. In contrast to primary localizedMLS, prognosis of
metastatic disease has significantly improved over the years.
Data Availability
)e data used to support the findings of this study are
available from the corresponding author upon request.
Additional Points
Increased age is associated with a higher probability of
having a round-cell component in MLS. )e tumor size and
tumor location are independent prognostic factors for
survival in MLS. )e use of, particularly preoperative, ra-
diotherapy for MLS has increased. )e overall survival of
localized MLS remained stable between 1989 and 2016. )e
overall survival of metastatic MLS increased between 1989
and 2016.
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Figure 4: )e use and the timing of RTduring the study period per
year in localized disease.
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Supplementary Materials
In this section, the baseline characteristics stratified by the
Round Cell Component (RCC) (Table 1) and absolute
overall (OS) survival rates stratified by age, tumor size, RCC,
and tumor location (Table 2) are presented for patients with
localized disease. Furthermore, an overview is given of the
associations for OS between RCC and patient and tumor
characteristics (Table 3). (Supplementary Materials)
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